CTOs on the Move

Agility Health

www.agilityhealth.com

 
Agility Health is a leading healthcare provider devoted to the rehabilitation of our patients' physical injuries and conditions. Established in 1968, Agility Health delivers personalized care through over one million therapy visits annually at more than 155 service sites in 20 states nationwide. Our team is dedicated to providing exceptional value to the patients, clients and partners we serve. Through our innovative clinical services, proven practice management systems and flexible partnerships, we help achieve optimal performance in a variety of settings, including outpatient clinics, hospitals, long-term care facilities and employer work sites. Agility Health is one of the top 10 rehabilitation services ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Careplus Health Plans Inc

Careplus Health Plans Inc is a Miami, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

American Medical Response

American Medical Response (AMR) is the nation`s leading medical transportation company serving more than 4,000 communities nationwide, and providing more than 4.8 million emergency and non-emergency patient transports each year. Every 10 seconds, our extensive network of more than 29,000 EMTs, paramedics, nurses, physicians, dispatchers and other professionals touch the lives of someone in need.

Unicare Health of Texas

Unicare Health of Texas is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Radia

Radia is a Everett, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Elcelyx Therapeutics

lcelyx was founded in 2010 with venture capital backing based on Gut Sensory Modulation (GSM) technology. Elcelyx`s proprietary, first-in-class Gut Sensory Modulators are delivered directly to the lower gut where they act on molecular targets to elicit physiological and pharmacological effects. The Elcelyx proprietary product candidate, NewMet for Type 2 diabetes is entering Phase 2b development and is a blockbuster opportunity designed to address the unmet needs in the oral anti-diabetic market. Elcelyx is led by an experienced management team and Board of Directors with track records of success in drug development and commercialization. Premier investors along with seasoned scientists and clinicians support the team. In September 2013, Elcelyx announced the formation of NaZura BioHealth Inc, a separate company established to focus on the development on non-NewMet assets.